Glaxosmithkline Plc (GSK) 45.15 $GSK
These Biotech's are Due for a Run
ACCESSWIRE - 2 hrs 10 mins ago
It's an Interesting Time in the Biotech Market, and with Labor Day on the Horizon, here's a few Biotechs that could Bring You Closer to Financial Independence
ACRX: 3.56 (-0.20), GSK: 45.15 (+0.12)
Global Adult Vaccines Company Analysis and Forecast 2007-2021 - Research and Markets
PR Newswire Europe - Thu Aug 04, 11:10AM CDT
Research and Markets has announced the addition of the "Global - Adult Vaccines Market - Company Analysis and Forecast to 2021" [http://www.researchandmarkets.com/research/fvbppv/global_adult] report to their offering.
MRK: 57.92 (+0.27), GSK: 45.15 (+0.12), NVS: 82.91 (+0.51)
Ionis Pharmaceuticals (IONS) Q2 Earnings: Stock to Beat?
Zacks Equity Research - Zacks Investment Research - Thu Aug 04, 7:08AM CDT
Ionis (IONS) is scheduled to report second-quarter 2016 results on Aug 9.
IPXL: 31.30 (-0.32), BIIB: 315.53 (-5.81), GSK: 45.15 (+0.12), IONS: 37.07 (-0.66)
ADAP: a Biotech Stock Using T-Cell Immunotherapy to Treat Cancer
Maher Syed - Zacks Investment Research - Mon Aug 01, 5:13PM CDT
Here's why Adaptimmune therapeutics looks like an intriguing investment prospect right now.
ADAP: 8.58 (-0.20), GSK: 45.15 (+0.12)
Karuna Pharmaceuticals Appoints Atul Pande, M.D., to Board of Directors
BusinessWire - Fri Jul 29, 9:00AM CDT
Karuna Pharmaceuticals, a company focused on targeting muscarinic receptors for the treatment of central nervous system disorders, today announced the appointment of Atul Pande, M.D., to its Board of Directors. Dr. Pande brings to Karuna more than 25 years of experience in the fields of psychiatry and neurosciences and an expertise in drug development.
AXON: 15.53 (+0.04), GSK: 45.15 (+0.12)
M Pharmaceutical Inc. Announces New U.S. Operating Company Located in Greater Cincinnati
Filing Services Canada XHTML - Fri Jul 29, 12:01AM CDT
GSK: 45.15 (+0.12)
Glaxo (GSK) Beats Q2 Earnings Estimates, Revenues Up Y/Y
Zacks Equity Research - Zacks Investment Research - Thu Jul 28, 9:59AM CDT
Glaxo (GSK) reported second-quarter 2016 core earnings of 70 cents per American depositary share, beating the Zacks Consensus Estimate of 55 cents.
INVA: 12.83 (-0.18), ANIP: 66.70 (+4.60), GSK: 45.15 (+0.12), NVS: 82.91 (+0.51)
Watch for GlaxoSmithKline to Potentially Pullback After Gaining 1.59% Yesterday
Comtex SmarTrend(R) - Wed Jul 27, 1:03PM CDT
GlaxoSmithKline (NYSE:GSK) traded in a range yesterday that spanned from a low of $44.79 to a high of $45.13. Yesterday, the shares gained 1.6%, which took the trading range above the 3-day high of $44.41 on volume of 4.0 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
GSK: 45.15 (+0.12)
SmarTrend Watching for Potential Pullback in Shares of GlaxoSmithKline After 1.59% Gain
Comtex SmarTrend(R) - Wed Jul 27, 1:01PM CDT
GlaxoSmithKline (NYSE:GSK) traded in a range yesterday that spanned from a low of $44.79 to a high of $45.13. Yesterday, the shares gained 1.6%, which took the trading range above the 3-day high of $44.41 on volume of 4.0 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
GSK: 45.15 (+0.12)
Novartis (NVS) Likely to Beat Q2 Earnings: Stock to Gain?
Zacks Equity Research - Zacks Investment Research - Fri Jul 15, 11:10AM CDT
Novartis AG (NVS) is scheduled to report second-quarter 2016 results on Jul 19.
JNJ: 123.87 (-0.03), GILD: 79.78 (-0.31), GSK: 45.15 (+0.12), NVS: 82.91 (+0.51)
Technical Report on Drug Manufacturers - Major Stocks - Bristol-Myers Squibb, AstraZeneca, Eli Lilly, and GlaxoSmithKline
PR Newswire - Mon Jul 11, 6:55AM CDT
On Friday, July 08, 2016, the NASDAQ Composite ended the trading session at 4,956.76, up 1.64%; the Dow Jones Industrial Average advanced 1.40%, to finish at 18,146.74; and the S&P 500 closed at 2,129.90, up 1.53%. The gains were broad based as all the sectors ended the session in positive. Stock-Callers.com has initiated coverage on the following equities: Bristol-Myers Squibb Company (NYSE: BMY), AstraZeneca PLC (NYSE: AZN), Eli Lilly and Company (NYSE: LLY), and GlaxoSmithKline PLC (NYSE: GSK). Learn more about these stocks by accessing their free notes at:
AZN: 34.34 (+0.25), LLY: 82.45 (-0.27), GSK: 45.15 (+0.12), BMY: 75.57 (+0.77)
Mylan Launches Generic Avodart® Capsules
PR Newswire - Fri Jun 24, 10:44AM CDT
Mylan N.V. (NASDAQ, TASE: MYL) today announced the U.S. launch of Dutasteride Capsules, 0.5 mg, the generic version of GlaxoSmithKline's Avodart® Capsules. Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product, which is indicated as monotherapy for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate to improve symptoms, reduce the risk of acute urinary retention and reduce the risk of the need for BPH-related surgery. It may also be used with tamsulosin for the treatment of symptomatic BPH in men with an enlarged prostate.
MYL: 48.84 (+0.43), GSK: 45.15 (+0.12)
AstraZeneca Nasal Spray Flu Vaccine To be Hit By ACIP Vote
Arpita Dutt - Zacks Investment Research - Thu Jun 23, 8:15AM CDT
With the ACIP voting that AstraZeneca's (AZN) FluMist Quadrivalent should not be used in the 2016-2017 flu season, demand will be limited.
JNJ: 123.87 (-0.03), PFE: 35.27 (-0.02), AZN: 34.34 (+0.25), GSK: 45.15 (+0.12)
New Stock Research Reports for June 21, 2016
Sheraz Mian - Zacks Investment Research - Tue Jun 21, 1:44PM CDT
New Stock Research Reports for June 21, 2016
FB: 124.39 (+1.88), DD: 68.82 (-0.09), CAT: 81.79 (-0.24), GSK: 45.15 (+0.12), INTC: 34.55 (+0.30), PEP: 108.14 (+0.10)
Glaxo/Innoviva's Closed Triple Combination Tops Phase III
Zacks Equity Research - Zacks Investment Research - Tue Jun 21, 8:30AM CDT
Glaxo (GSK) and Innoviva (INVA) announced positive top-line data from the phase III FULFIL study on the closed triple combination therapy for the treatment of COPD.
INVA: 12.83 (-0.18), TBPH: 24.37 (-0.25), GSK: 45.15 (+0.12), BMY: 75.57 (+0.77)
Look for Shares of GlaxoSmithKline to Potentially Pullback after Yesterday's 3.24% Rise
Comtex SmarTrend(R) - Mon Jun 20, 2:15PM CDT
GlaxoSmithKline (NYSE:GSK) traded in a range yesterday that spanned from a low of $41.62 to a high of $42.28. Yesterday, the shares gained 3.2%, which took the trading range above the 3-day high of $40.67 on volume of 4.0 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
GSK: 45.15 (+0.12)
SmarTrend Watching for Potential Pullback in Shares of GlaxoSmithKline After 3.24% Gain
Comtex SmarTrend(R) - Mon Jun 20, 2:13PM CDT
GlaxoSmithKline (NYSE:GSK) traded in a range yesterday that spanned from a low of $41.62 to a high of $42.28. Yesterday, the shares gained 3.2%, which took the trading range above the 3-day high of $40.67 on volume of 4.0 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
GSK: 45.15 (+0.12)
February 2017 Options Now Available For GlaxoSmithKline (GSK)
DividendChannel.com - Mon Jun 20, 10:01AM CDT
Investors in GlaxoSmithKline plc saw new options begin trading today, for the February 2017 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 242 days until expiration the...
GSK: 45.15 (+0.12)
Watch for GlaxoSmithKline to Potentially Rebound After Falling 2.13% Yesterday
Comtex SmarTrend(R) - Tue Jun 14, 1:10PM CDT
GlaxoSmithKline (NYSE:GSK) traded in a range yesterday that spanned from a low of $39.76 to a high of $40.40. Yesterday, the shares fell 2.1%, which took the trading range below the 3-day low of $40.77 on volume of 3.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
GSK: 45.15 (+0.12)
Milner Therapeutics Institute Announces New Partnership With Japanese Pharmaceutical Company Shionogi
PR Newswire Europe - Mon Jun 13, 4:51AM CDT
CAMBRIDGE, England, June 13, 2016 /PRNewswire/ --
GSK: 45.15 (+0.12)
These Biotech's are Due for a Run
ACCESSWIRE - 2 hrs 10 mins ago
It's an Interesting Time in the Biotech Market, and with Labor Day on the Horizon, here's a few Biotechs that could Bring You Closer to Financial Independence
ACRX: 3.56 (-0.20), GSK: 45.15 (+0.12)
Global Adult Vaccines Company Analysis and Forecast 2007-2021 - Research and Markets
PR Newswire Europe - Thu Aug 04, 11:10AM CDT
Research and Markets has announced the addition of the "Global - Adult Vaccines Market - Company Analysis and Forecast to 2021" [http://www.researchandmarkets.com/research/fvbppv/global_adult] report to their offering.
MRK: 57.92 (+0.27), GSK: 45.15 (+0.12), NVS: 82.91 (+0.51)
Ionis Pharmaceuticals (IONS) Q2 Earnings: Stock to Beat?
Zacks Equity Research - Zacks Investment Research - Thu Aug 04, 7:08AM CDT
Ionis (IONS) is scheduled to report second-quarter 2016 results on Aug 9.
IPXL: 31.30 (-0.32), BIIB: 315.53 (-5.81), GSK: 45.15 (+0.12), IONS: 37.07 (-0.66)
ADAP: a Biotech Stock Using T-Cell Immunotherapy to Treat Cancer
Maher Syed - Zacks Investment Research - Mon Aug 01, 5:13PM CDT
Here's why Adaptimmune therapeutics looks like an intriguing investment prospect right now.
ADAP: 8.58 (-0.20), GSK: 45.15 (+0.12)
Karuna Pharmaceuticals Appoints Atul Pande, M.D., to Board of Directors
BusinessWire - Fri Jul 29, 9:00AM CDT
Karuna Pharmaceuticals, a company focused on targeting muscarinic receptors for the treatment of central nervous system disorders, today announced the appointment of Atul Pande, M.D., to its Board of Directors. Dr. Pande brings to Karuna more than 25 years of experience in the fields of psychiatry and neurosciences and an expertise in drug development.
AXON: 15.53 (+0.04), GSK: 45.15 (+0.12)
M Pharmaceutical Inc. Announces New U.S. Operating Company Located in Greater Cincinnati
Filing Services Canada XHTML - Fri Jul 29, 12:01AM CDT
GSK: 45.15 (+0.12)
Glaxo (GSK) Beats Q2 Earnings Estimates, Revenues Up Y/Y
Zacks Equity Research - Zacks Investment Research - Thu Jul 28, 9:59AM CDT
Glaxo (GSK) reported second-quarter 2016 core earnings of 70 cents per American depositary share, beating the Zacks Consensus Estimate of 55 cents.
INVA: 12.83 (-0.18), ANIP: 66.70 (+4.60), GSK: 45.15 (+0.12), NVS: 82.91 (+0.51)
Watch for GlaxoSmithKline to Potentially Pullback After Gaining 1.59% Yesterday
Comtex SmarTrend(R) - Wed Jul 27, 1:03PM CDT
GlaxoSmithKline (NYSE:GSK) traded in a range yesterday that spanned from a low of $44.79 to a high of $45.13. Yesterday, the shares gained 1.6%, which took the trading range above the 3-day high of $44.41 on volume of 4.0 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
GSK: 45.15 (+0.12)
SmarTrend Watching for Potential Pullback in Shares of GlaxoSmithKline After 1.59% Gain
Comtex SmarTrend(R) - Wed Jul 27, 1:01PM CDT
GlaxoSmithKline (NYSE:GSK) traded in a range yesterday that spanned from a low of $44.79 to a high of $45.13. Yesterday, the shares gained 1.6%, which took the trading range above the 3-day high of $44.41 on volume of 4.0 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
GSK: 45.15 (+0.12)
Novartis (NVS) Likely to Beat Q2 Earnings: Stock to Gain?
Zacks Equity Research - Zacks Investment Research - Fri Jul 15, 11:10AM CDT
Novartis AG (NVS) is scheduled to report second-quarter 2016 results on Jul 19.
JNJ: 123.87 (-0.03), GILD: 79.78 (-0.31), GSK: 45.15 (+0.12), NVS: 82.91 (+0.51)
Technical Report on Drug Manufacturers - Major Stocks - Bristol-Myers Squibb, AstraZeneca, Eli Lilly, and GlaxoSmithKline
PR Newswire - Mon Jul 11, 6:55AM CDT
On Friday, July 08, 2016, the NASDAQ Composite ended the trading session at 4,956.76, up 1.64%; the Dow Jones Industrial Average advanced 1.40%, to finish at 18,146.74; and the S&P 500 closed at 2,129.90, up 1.53%. The gains were broad based as all the sectors ended the session in positive. Stock-Callers.com has initiated coverage on the following equities: Bristol-Myers Squibb Company (NYSE: BMY), AstraZeneca PLC (NYSE: AZN), Eli Lilly and Company (NYSE: LLY), and GlaxoSmithKline PLC (NYSE: GSK). Learn more about these stocks by accessing their free notes at:
AZN: 34.34 (+0.25), LLY: 82.45 (-0.27), GSK: 45.15 (+0.12), BMY: 75.57 (+0.77)
Mylan Launches Generic Avodart® Capsules
PR Newswire - Fri Jun 24, 10:44AM CDT
Mylan N.V. (NASDAQ, TASE: MYL) today announced the U.S. launch of Dutasteride Capsules, 0.5 mg, the generic version of GlaxoSmithKline's Avodart® Capsules. Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product, which is indicated as monotherapy for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate to improve symptoms, reduce the risk of acute urinary retention and reduce the risk of the need for BPH-related surgery. It may also be used with tamsulosin for the treatment of symptomatic BPH in men with an enlarged prostate.
MYL: 48.84 (+0.43), GSK: 45.15 (+0.12)
AstraZeneca Nasal Spray Flu Vaccine To be Hit By ACIP Vote
Arpita Dutt - Zacks Investment Research - Thu Jun 23, 8:15AM CDT
With the ACIP voting that AstraZeneca's (AZN) FluMist Quadrivalent should not be used in the 2016-2017 flu season, demand will be limited.
JNJ: 123.87 (-0.03), PFE: 35.27 (-0.02), AZN: 34.34 (+0.25), GSK: 45.15 (+0.12)
New Stock Research Reports for June 21, 2016
Sheraz Mian - Zacks Investment Research - Tue Jun 21, 1:44PM CDT
New Stock Research Reports for June 21, 2016
FB: 124.39 (+1.88), DD: 68.82 (-0.09), CAT: 81.79 (-0.24), GSK: 45.15 (+0.12), INTC: 34.55 (+0.30), PEP: 108.14 (+0.10)
Glaxo/Innoviva's Closed Triple Combination Tops Phase III
Zacks Equity Research - Zacks Investment Research - Tue Jun 21, 8:30AM CDT
Glaxo (GSK) and Innoviva (INVA) announced positive top-line data from the phase III FULFIL study on the closed triple combination therapy for the treatment of COPD.
INVA: 12.83 (-0.18), TBPH: 24.37 (-0.25), GSK: 45.15 (+0.12), BMY: 75.57 (+0.77)
Look for Shares of GlaxoSmithKline to Potentially Pullback after Yesterday's 3.24% Rise
Comtex SmarTrend(R) - Mon Jun 20, 2:15PM CDT
GlaxoSmithKline (NYSE:GSK) traded in a range yesterday that spanned from a low of $41.62 to a high of $42.28. Yesterday, the shares gained 3.2%, which took the trading range above the 3-day high of $40.67 on volume of 4.0 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
GSK: 45.15 (+0.12)
SmarTrend Watching for Potential Pullback in Shares of GlaxoSmithKline After 3.24% Gain
Comtex SmarTrend(R) - Mon Jun 20, 2:13PM CDT
GlaxoSmithKline (NYSE:GSK) traded in a range yesterday that spanned from a low of $41.62 to a high of $42.28. Yesterday, the shares gained 3.2%, which took the trading range above the 3-day high of $40.67 on volume of 4.0 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
GSK: 45.15 (+0.12)
February 2017 Options Now Available For GlaxoSmithKline (GSK)
DividendChannel.com - Mon Jun 20, 10:01AM CDT
Investors in GlaxoSmithKline plc saw new options begin trading today, for the February 2017 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 242 days until expiration the...
GSK: 45.15 (+0.12)
Watch for GlaxoSmithKline to Potentially Rebound After Falling 2.13% Yesterday
Comtex SmarTrend(R) - Tue Jun 14, 1:10PM CDT
GlaxoSmithKline (NYSE:GSK) traded in a range yesterday that spanned from a low of $39.76 to a high of $40.40. Yesterday, the shares fell 2.1%, which took the trading range below the 3-day low of $40.77 on volume of 3.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
GSK: 45.15 (+0.12)
Milner Therapeutics Institute Announces New Partnership With Japanese Pharmaceutical Company Shionogi
PR Newswire Europe - Mon Jun 13, 4:51AM CDT
CAMBRIDGE, England, June 13, 2016 /PRNewswire/ --
GSK: 45.15 (+0.12)
